Timing of Antiplatelet and Anticoagulant Therapy Resumption Following Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis
Clinical Gastroenterology and Hepatology · 2026-07
DOI: 10.1016/j.cgh.2026.07.002 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-07. Verfasst von Yihang Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore; Centre of AI in Medicine, Nanyang Technological University…. Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors, Gastrointestinal Hemorrhage, Anticoagulants. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nanyang Technological University.
Abstract (Originalsprache)
BACKGROUND & AIMS: Gastrointestinal bleeding is a major complication in patients receiving antithrombotic therapy. Following gastrointestinal bleeding, clinicians face a critical dilemma: resuming therapy risks rebleeding, whereas discontinuation increases thrombotic events and mortality. This meta-analysis aimed to quantify the risks and benefits of antithrombotic therapy resumption vs discontinuation following gastrointestinal bleeding, and to evaluate the impact of resumption timing on recurrent gastrointestinal bleeding, major vascular events, and all-cause mortality. METHODS: We searched Embase, Scopus, PubMed, Web of Science, and Cochrane Library from inception to September 2025 for studies comparing antithrombotic therapy resumption vs delayed resumption or discontinuation after gastrointestinal bleeding. This review was registered with PROSPERO (CRD420251141360). RESULTS: Twenty-one studies were included. Antiplatelet therapy resumption reduced major vascular events (hazard ratio, 0.70; 95% confidence interval, 0.60-0.83; absolute risk difference, -3.6%) and mortality (hazard ratio, 0.44; 95% confidence interval, 0.26-0.76; absolute risk difference, -10.0%), but increased recurrent gastrointestinal bleeding (hazard ratio, 1.42; 95% confidence interval, 1.09-1.84; absolute risk difference, +2.2%). Similarly, anticoagulant therapy resumption reduced major vascular events (hazard ratio, 0.45; 95% confidence interval, 0.34-0.58; absolute risk difference, -7.0%) and mortality (hazard ratio, 0.53; 95% confidence interval, 0.43-0.65; absolute risk difference, -11.1%), but increased recurrent gastrointestinal bleeding (hazard ratio, 1.59; 95% confidence interval, 1.38-1.83; absolute risk difference, +2.6%). Notably, early resumption of both antiplatelet therapy and anticoagulant therapy within 7 days significantly reduced major vascular events (hazard ratio, 0.39; 95% confidence interval, 0.19-0.78; absolute risk difference, -11.4%) but increased recurrent gastrointestinal bleeding (hazard ratio, 1.49; 95% confidence interval, 1.18-1.89; absolute risk difference, +2.7%), with no significant difference in mortality (hazard ratio, 0.78; 95% confidence interval, 0.29-2.10; absolute risk difference, -4.7%). CONCLUSIONS: Both antiplatelet therapy and anticoagulant therapy resumption after gastrointestinal bleeding provide substantial clinical benefits despite increased recurrent gastrointestinal bleeding risk. Early resumption (≤7 days) offers favorable benefit-risk balance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore; Centre of AI in Medicine, Nanyang Technological University, Singapore, Singapore.
- The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China.
- The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China. Electronic address: kelvintsoi@cuhk.edu.hk.
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore; Centre of AI in Medicine, Nanyang Technological University, Singapore, Singapore. Electronic address: josephsung@ntu.edu.sg.
Förderung
- Nanyang Technological University
Zitieren
APA
Liu, Y., Hu, Y., Song, S., Goh, W. W. B., Tsoi, K. K. F., & Sung, J. J. Y. (2026). Timing of Antiplatelet and Anticoagulant Therapy Resumption Following Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.07.002
Vancouver
Liu Y, Hu Y, Song S, Goh WWB, Tsoi KKF, Sung JJY. Timing of Antiplatelet and Anticoagulant Therapy Resumption Following Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.07.002
BibTeX
@article{Liu2026,
author = {Liu, Yihang and Hu, Yaxin and Song, Shangzheng and Goh, Wilson Wen Bin and Tsoi, Kelvin K F and Sung, Joseph J Y},
title = {Timing of Antiplatelet and Anticoagulant Therapy Resumption Following Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
doi = {10.1016/j.cgh.2026.07.002}
}
EUVIMED